Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a single palliative care visit improve life for bone metastasis patients?

NCT ID NCT06805396

Symptom relief Sponsor: Roxanne Gal Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether offering a palliative care consultation early—when patients with advanced cancer and bone metastases start radiotherapy—improves their satisfaction with care and quality of life. About 246 participants will be randomly assigned to receive either a tailored palliative care consult within two weeks or standard care. The goal is to see if early, integrated palliative care helps manage symptoms and emotional distress better than waiting until later.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
palliative care consultation
What this could lead to
If it works, this could show that early palliative care consults improve patient satisfaction and quality of life for people with bone metastases.
What could go wrong
This is a moderate-sized Phase 2 trial, so results may not apply to all patients. The intervention is a single consult, which may not be enough to change outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 246 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. broad informed consent for PRESENT+ (i.e., consent for filling out questionnaires at regular intervals and randomization into future intervention studies), and 2. having their treating physician in the TIPZO-RT study site (UMC Utrecht, Radboudumc or LUMC). Exclusion Criteria: 1. not able to understand the objective of the study (in Dutch), 2. cognitive impairment or dementia, and 3. has been in contact with palliative care consultants of the hospital PCCT before.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone metastases in subjects with advanced cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic carcinoma in the bone metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone metastases in subjects with advanced cancer Radiotherapy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Alrijne Ziekenhuis

    RECRUITING

    Leiden, Netherlands

  • Groene Hart Ziekenhuis

    RECRUITING

    Gouda, Netherlands

  • LUMC

    RECRUITING

    Leiden, Netherlands

  • Meander MC

    RECRUITING

    Amersfoort, Netherlands

  • Radboudumc

    RECRUITING

    Nijmegen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.